These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32730625)

  • 1. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States.
    Neilan AM; Bulteel AJB; Hosek SG; Foote JHA; Freedberg KA; Landovitz RJ; Walensky RP; Resch SC; Kazemian P; Paltiel AD; Weinstein MC; Wilson CM; Ciaranello AL
    Clin Infect Dis; 2021 Oct; 73(7):e1927-e1935. PubMed ID: 32730625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price.
    Amick AK; Eskibozkurt GE; Hosek SG; Flanagan CF; Landovitz RJ; Jin EY; Wilson CM; Freedberg KA; Weinstein MC; Kazemian P; Paltiel AD; Ciaranello AL; Neilan AM
    Clin Infect Dis; 2024 Feb; 78(2):402-410. PubMed ID: 37823865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.
    Long EF; Brandeau ML; Owens DK
    Ann Intern Med; 2010 Dec; 153(12):778-89. PubMed ID: 21173412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of hepatitis C virus test-and-treat and risk reduction strategies among men who have sex with men living with HIV in France.
    Castry M; Cousien A; Champenois K; Supervie V; Velter A; Ghosn J; Yazdanpanah Y; Paltiel AD; Deuffic-Burban S
    J Int AIDS Soc; 2022 Dec; 25(12):e26035. PubMed ID: 36451286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA.
    Juusola JL; Brandeau ML; Long EF; Owens DK; Bendavid E
    AIDS; 2011 Sep; 25(14):1779-87. PubMed ID: 21716076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections.
    Neilan AM; Bangs AC; Hudgens M; Patel K; Agwu AL; Bassett IV; Gaur AH; Hyle EP; Crespi CM; Horvath KJ; Dugdale CM; Powers KA; Rendina HJ; Weinstein MC; Walensky RP; Freedberg KA; Ciaranello AL
    AIDS Behav; 2021 Sep; 25(9):2973-2984. PubMed ID: 33547993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK.
    Macgregor L; Ward Z; Martin NK; Nicholls J; Desai M; Hickson F; Weatherburn P; Hickman M; Vickerman P
    J Viral Hepat; 2021 Jun; 28(6):897-908. PubMed ID: 33759257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
    Mauskopf J; Brogan A; Martin S; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
    Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
    Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.
    Hyle EP; Jani IV; Lehe J; Su AE; Wood R; Quevedo J; Losina E; Bassett IV; Pei PP; Paltiel AD; Resch S; Freedberg KA; Peter T; Walensky RP
    PLoS Med; 2014 Sep; 11(9):e1001725. PubMed ID: 25225800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility of HIV Testing Programs Among Men Who Have Sex with Men in the United States.
    Zulliger R; Maulsby C; Solomon L; Baytop C; Orr A; Nasrullah M; Shouse L; DiNenno E; Holtgrave D
    AIDS Behav; 2017 Mar; 21(3):619-625. PubMed ID: 27624729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men.
    Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Welton ML; Palefsky JM
    JAMA; 1999 May; 281(19):1822-9. PubMed ID: 10340370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India.
    Venkatesh KK; Becker JE; Kumarasamy N; Nakamura YM; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP; Freedberg KA
    PLoS One; 2013; 8(5):e64604. PubMed ID: 23741348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness.
    Bassett IV; Govindasamy D; Erlwanger AS; Hyle EP; Kranzer K; van Schaik N; Noubary F; Paltiel AD; Wood R; Walensky RP; Losina E; Bekker LG; Freedberg KA
    PLoS One; 2014; 9(1):e85197. PubMed ID: 24465503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States.
    Shah M; Risher K; Berry SA; Dowdy DW
    Clin Infect Dis; 2016 Jan; 62(2):220-229. PubMed ID: 26362321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.